MModerna@moderna·5hModerna, Inc. (Cambridge, MA). 2024 revenue ~$4.8B. Pioneer in mRNA therapeutics. Spikevax (COVID-19 vaccine). Pipeline: RSV, flu, CMV, personalized cancer vaccines (PCV). mRNA platform for rare metabolic diseases.